COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, explained the intricacies of how geopolitical issues, like the COVID-19 pandemic and inflation, impact pharmaceuticals and contribute to ongoing drug supply shortages.
The annual meeting of the International Generic and Biosimilar Medicines Association (IGBA) was held in Orlando, Florida, from February 15 to February 16.
How has the COVID-19 pandemic contributed to supply chain issues within the pharmaceutical industry, including biologics and biosimilars?
Mansoura: From my perspective, the most dramatic evidence of this intersection of COVID-19 and supply chains with medical pharmaceuticals, is the recognition of the criticality of these assets for national and economic security.
In large part, it's because of the access to diagnostics, therapeutics, and of course, vaccines that allowed in large part the restoration to some sort of new normal, if you will, of how we go about our daily lives—school, work, play. And it was, again, in large part access.
So, the intersection of national security with the biopharma medical supply ecosystem, industrial-based supply chain has been core to the work we've been doing at MITRE and the work that I've been doing in various capacities over the last 20-plus years.
Beside the COVID-19 pandemic, how have other geopolitical issues factored into drug supply shortages and government entities abilities to address them?
Mansoura: This heightened awareness of how important access to medicines, drugs, and again, what we would call national security assets, COVID-19 vaccines, has really been heightened by not only COVID-19, of course, but I think through the CHIPS [the Creating Helpful Incentives to Produce Semiconductors] and Science Act, the broader discussions that are going on in the US and around the world about access to key technologies, whether it's semiconductors or AI [artificial intelligence] or autonomous vehicles, electric batteries, or Russian oil.
I think an awareness of the resiliency, the surety, and security of access to key assets like that, that really are critical to our national and economic security. I think many of us—as consumers but also as professionals in this space—have responsibilities to ensure sort of the surety and security of access to critical assets. There is clearly a shift in in attention to this through legislation, through policy, through executive orders, and through everyday public discourse. So, clearly heightened sensitivity.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.